When Willow, an active, healthy five-year-old began experiencing unusual symptoms like decreased appetite and fatigue, her mother, Valerie, didn’t assume the worst. But after her bloodwork came back abnormal – showing a critically low platelet count – Valerie’s concerns grew. It was around midnight the following day when a medical team from Children’s National Hospital in DC delivered the news that Willow had acute lymphoblastic leukemia (ALL).

Receiving a diagnosis of any kind has implications not just for the person on the receiving end, but also for their family, friends and the people closest to them. As part of our commitment to patients and their care teams, this National Family Caregivers Month, we shine a light on this essential role and its many nuances. 

During National Family Caregivers Month, we recognize and honor family caregivers who dedicate time and resources to caring for their loved ones. Jazz is committed to raising awareness of the essential role that caregivers play and the challenges they face, and to educating communities on ways to increase support for them.

HER2 plays an important role in cell growth and survival, but many cancers, including gastroesophageal adenocarcinoma (GEA), can overexpress this protein, leading to uncontrolled cell growth and impacting prognosis. While not everyone diagnosed with a GEA will be HER2-positive, it is helpful to test for HER2 as the presence of this protein can help inform the treatment approach.

Bispecific antibodies are showing potential in the fight against HER2-expressing cancers. This innovative approach is designed to target two specific protein receptors, providing a new and effective way to treat aggressive forms of cancer that overexpress the HER2 protein. With their ability to simultaneously target two different antigens, bispecific antibodies offer a novel approach to treating solid tumors, including the possibility for new first-line treatments. 

Given the limited recognition of idiopathic hypersomnia, there is not substantial data on the burden of symptoms on those living with the disorder. Recent real-world evidence from a self-reported survey published in Nature and Science of Sleep reveals more insights around idiopathic hypersomnia symptoms and patients’ satisfaction with treatment regimens.

Developmental and Epileptic Encephalopathies (DEEs) are a group of rare and severe epilepsies which are characterized by seizures and significant developmental delays. Most DEEs begin in early life, often in infancy, with children experiencing frequent and severe seizures, which can be of multiple types. This generates a complex clinical picture in which both developmental abnormalities and severe epilepsy contribute to the functional impairment of these children which continues into adulthood.

In this video, watch Mat Davis, PhD, Vice President, Head of Data Science, Evidence and Value Generation, discuss how we leverage focused and integrated quantitative methods in our R&D process to transform patient lives.

Establishing expert consensus treatment recommendations is imperative to providing more people with consistent care. As a leader in neuroscience, we are committed to empowering those we serve through innovative science and thoughtful real-world evidence.